You are here

DX-2930

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Endpoints

Thu, 05/18/17 - 09:38 am

Dyax banks on drug designation news

Bizjournals.com

Tue, 07/7/15 - 12:28 pm

hereditary angiodema

Dyax's Threat to $630,000 Shire Drug Makes It a Target

Bloomberg

Thu, 06/11/15 - 10:13 am

hereditary angiodema

Dyax shares jump on drug study, FDA fast-track status

Marketwatch

Tue, 03/31/15 - 05:53 pm

hereditary angiodema

This Company Is Focused on Delivering Value to Patients and Shareholders

Motley Fool

Sun, 10/6/13 - 09:19 am